The latest announcement is out from Genfit SA ( (GNFT) ).
On March 20, 2025, GENFIT announced the completion of a non-dilutive royalty financing agreement with HealthCare Royalty (HCRx) for up to €185 million, which includes an upfront payment of €130 million. This financing extends GENFIT’s cash runway beyond 2027, supporting its R&D efforts and reducing its convertible debt significantly. The transaction was approved by OCEANE bondholders on March 10, 2025, and will allow GENFIT to focus on its ACLF pipeline development and other corporate purposes. The repurchase of 2025 OCEANEs will occur on March 26, 2025, with a consent fee payment scheduled for April 14, 2025.
More about Genfit SA
GENFIT is a biopharmaceutical company focused on developing treatments for rare and life-threatening liver diseases. With a strong history in liver disease research, GENFIT is advancing a diverse R&D portfolio, particularly in Acute-on-Chronic Liver Failure (ACLF) and other serious conditions such as cholangiocarcinoma and urea cycle disorder. The company is also involved in diagnostics, with products like NIS2+® for Metabolic dysfunction-associated steatohepatitis. GENFIT is headquartered in Lille, France, with additional offices in Paris, Zurich, and Cambridge, MA.
YTD Price Performance: -5.74%
Average Trading Volume: 8,233
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $183.4M
For detailed information about GNFT stock, go to TipRanks’ Stock Analysis page.